ADC Therapeutics SA ADCT

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
+$0.09 (+5.14%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

Relative Strength Index (RSI)

- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

- The RSI is calculated using the following formula:

RSI = 100 - (100 / (1 + RS))

Where RS is the ratio of the average gains to the average losses over a specified period.

- The default time period used is 14 days.

- RSI values range between 0 and 100.

RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

About

Business overview of ADC Therapeutics SA (ADCT)
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.

Key Insights

Critical company metrics and information

  • Latest Closing Price

    $1.84

  • Market Cap

    $177.91 Million

  • Price-Earnings Ratio

    -0.77

  • Total Outstanding Shares

    96.69 Million Shares

  • Total Employees

    274

  • Dividend

    No dividend

  • IPO Date

    May 15, 2020

  • SIC Description

    Pharmaceutical Preparations

  • Primary Exchange

    New York Stock Exchange

  • Type

    Common Stock

  • Headquarters

    Biopole, Epalinges, V8, 1066

  • Homepage

    https://www.adctherapeutics.com

Historical Stock Splits

If you bought 7 shares of ADCT before May 10, 2005, you'd have 1 share today.
Execution DateSplit Amount
May 10, 20051-for-7 (Reverse Split)

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow, Continuing$-36.55 Million
Exchange Gains/Losses$412,000
Net Cash Flow From Investing Activities$-1.10 Million
Net Cash Flow From Investing Activities, Continuing$-1.10 Million
Net Cash Flow From Operating Activities$-133.62 Million
Net Cash Flow From Financing Activities$98.17 Million

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Research and Development$112.86 Million
Net Income/Loss Available To Common Stockholders, Basic$-212.15 Million
Income/Loss From Continuing Operations After Tax$-208.62 Million
Income Tax Expense/Benefit$43.66 Million
Income/Loss From Equity Method Investments$-3.53 Million
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0

Comprehensive Income

October 1, 2023 to September 30, 2024
MetricValue
Other Comprehensive Income/Loss Attributable To Parent$-896,000
Comprehensive Income/Loss Attributable To Parent$-213.05 Million
Comprehensive Income/Loss Attributable To Noncontrolling Interest$0
Other Comprehensive Income/Loss$-213.05 Million
Comprehensive Income/Loss$-213.05 Million

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Noncurrent Assets$16.07 Million
Assets$349.08 Million
Noncurrent Liabilities$453.35 Million
Other Current Assets$316.93 Million
Equity$-171.95 Million
Current Assets$333.00 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends

Recent Headlines From The Web

Latest news, press releases, and media coverage about ADCT from trusted financial sources
    All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

    â“’ 2025 Financhle. All Rights Reserved.